Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Cannot have received: calcineurin inhibitor (tacrolimus)

Tacrolimus within 6 months prior to the first dosing

Cannot have received: antimetabolite (methotrexate)

Methotrexate within 5 half-lives or 90 days after last dose (whichever is longer)

Cannot have received: anti-FcRn inhibitor (efgartigimod)

Anti-FcRn inhibitors (ex. Efgartigimod) within 5 half-lives or 90 days after last dose (whichever is longer)

Cannot have received: C5 complement inhibitor (eculizumab)

C5 complement inhibitor (ex. Eculizumab) within 5 half-lives or 90 days after last dose (whichever is longer)

Cannot have received: anti-CD20 (rituximab)

Anti-CD20 (ex. Rituximab) within 5 half-lives for 90 days after last dose (whichever is longer)

Cannot have received: immunoglobulin (SCIg, IVIg)

immunoglobulins given SC or IV (SCIg or IVIg) within 4 weeks before Screening

Cannot have received: plasmapheresis/plasma exchange

plasmapheresis/plasma exchange (PE) within 4 weeks before Screening

Cannot have received: investigational therapy

Exception: other than CNP-106

investigational therapy other than CNP-106 within 28 days or 5 half-lives, whichever is longer, prior to Screening